Psychedelic Science
Clinical research, therapeutic applications, the renaissance of psychedelic medicine.
Mainstream bestseller covering the history and renaissance of psychedelic research. Follows clinical trials at Johns Hopkins and NYU, interviews researchers, and describes the author's own guided sessions.
Comprehensive review of classic psychedelic pharmacology by a leading medicinal chemist. Covers structure-activity relationships, receptor binding profiles, and mechanisms of action for LSD, psilocybin, mescaline, and DMT.
MAPS-sponsored Phase 3 trial showing MDMA-assisted therapy produced significant PTSD symptom reduction. 67% of participants no longer met diagnostic criteria after treatment.
Documentary exploring the role of fungi in ecosystems, medicine, and human consciousness. Features Paul Stamets and researchers from the Johns Hopkins psilocybin trials.
Documentary following MDMA-assisted therapy sessions for PTSD in Israeli and Palestinian patients. One of the few films showing actual therapeutic sessions with psychedelic medicines.
Johns Hopkins trial showing a single psilocybin session produced clinically significant reductions in depression and anxiety in cancer patients, sustained at 6-month follow-up. One of the pivotal papers in the psychedelic renaissance.
Open-label Imperial College trial showing psilocybin produced marked reductions in depression scores in treatment-resistant patients. An early clinical demonstration of psilocybin's antidepressant potential.
Long-form article that preceded Pollan's book, profiling the NYU and Johns Hopkins psilocybin cancer-anxiety trials. Brought psychedelic research to The New Yorker's mainstream audience.
Proposes that psychedelics increase neural entropy — the brain's information-theoretic complexity — offering a mechanistic framework for both the psychedelic experience and its therapeutic applications.
National Geographic documentary covering LSD's history, pharmacology, and ongoing research. Includes interviews with researchers and footage from clinical settings.
Landmark NIH trial demonstrating that a single IV ketamine infusion produced rapid antidepressant effects within hours in treatment-resistant patients. Launched the ketamine-for-depression research field.
First rigorously controlled study to demonstrate that psilocybin reliably produces mystical experiences rated by participants as among the most meaningful of their lives. Restarted modern psychedelic research at Johns Hopkins.
Edited anthology of key papers spanning clinical research, anthropology, and neuroscience. Includes work by Hofmann, Grof, Strassman, Schultes, and other foundational figures.
Account of the first FDA-approved clinical research with DMT in decades. Documents dose-response data and phenomenological reports from 60 volunteers at the University of New Mexico.
MAPS-run psychedelic peer support service at festivals and events. Provides safe spaces and trained volunteers for people experiencing difficult psychedelic states. A model for psychedelic harm reduction in practice.
The organization that funded and coordinated MDMA-assisted therapy through FDA clinical trials. Extensive research archive, policy documents, and educational materials.
Leading academic psychedelic research group. Published foundational work on default mode network disruption, the entropic brain hypothesis, and psilocybin for depression.
Interview-format podcast with researchers, clinicians, and policy experts in the psychedelic therapy space. Covers clinical trials, regulatory developments, and therapeutic frameworks.
Know something that should be here?
Suggest an addition →